Literature DB >> 1616362

Follow up study of labial salivary gland lesions in primary Sjögren's syndrome.

J P Leroy1, Y L Pennec, C Soulier, J M Berthelot, G Letoux, P Youinou.   

Abstract

Labial salivary gland biopsy samples were taken from 27 patients with primary Sjögren's syndrome (SS), 10 with rheumatoid arthritis (RA) and secondary SS, and four normal control subjects on two occasions at intervals of more than one year. In the former group of patients, eight of the nine initially negative analyses were positive on the second sample, whereas two of the seven patients with RA and secondary SS were negative for the first sample and then positive for the second. In primary SS, the mean (SD) variation of the focus score was 1.7 (2.6) and that of salivary duct infiltration 0.2 (0.7). The former correlated well with the latter.

Entities:  

Mesh:

Year:  1992        PMID: 1616362      PMCID: PMC1004745          DOI: 10.1136/ard.51.6.777

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  24 in total

1.  Salivary gland echography in patients with Sjögren's syndrome.

Authors:  H Kawamura; N Taniguchi; K Itoh; S Kano
Journal:  Arthritis Rheum       Date:  1990-04

2.  Comparison of labial and sublingual salivary gland biopsies in the diagnosis of Sjögren's syndrome.

Authors:  Y L Pennec; J P Leroy; J Jouquan; A Lelong; P Katsikis; P Youinou
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

3.  Morphometric study of salivary glands in primary Sjögren's syndrome.

Authors:  P Manganelli; F Salaffi; A Nervetti; N Raffaini; G Olivetti
Journal:  Clin Exp Rheumatol       Date:  1989 May-Jun       Impact factor: 4.473

4.  Salivary lactoferrin in primary Sjögren's syndrome.

Authors:  N Jezequel; F Depasse; J Jouquan; A Lelong; S Roncin; G Pare; Y L Pennec; P Youinou
Journal:  Clin Exp Rheumatol       Date:  1989 Mar-Apr       Impact factor: 4.473

5.  Parotid sialography and minor salivary gland biopsy in the diagnosis of Sjögren's syndrome. A comparative study of 84 patients.

Authors:  C Vitali; A Tavoni; U Simi; G Marchetti; P Vigorito; A d'Ascanio; R Neri; R Cristofani; S Bombardieri
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

6.  Periductal lymphocytic infiltrates in salivary glands in myasthenia gravis patients lacking Sjögren's syndrome.

Authors:  G Lindahl; A K Lefvert; E Hedfors
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

7.  Sjögren's syndrome. Proposed criteria for classification.

Authors:  R I Fox; C A Robinson; J G Curd; F Kozin; F V Howell
Journal:  Arthritis Rheum       Date:  1986-05

8.  Salivary flow rates and iodide trapping capacity in patients with Sjögren's syndrome.

Authors:  D K Mason; R M Harden; J A Boyle; M K Jasani; J Williamson; W W Buchanan
Journal:  Ann Rheum Dis       Date:  1967-07       Impact factor: 19.103

9.  Virus infection induces redistribution and membrane localization of the nuclear antigen La (SS-B): a possible mechanism for autoimmunity.

Authors:  C Baboonian; P J Venables; J Booth; D G Williams; L M Roffe; R N Maini
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

10.  Lymphocytic infiltrates and epithelial HLA-DR expression in lip salivary glands in connective tissue disease patients lacking sicca: a prospective study.

Authors:  G Lindahl; E Hedfors
Journal:  Br J Rheumatol       Date:  1989-08
View more
  9 in total

Review 1.  The oral component of Sjögren's syndrome: pass the scalpel and check the water.

Authors:  Ava J Wu
Journal:  Curr Rheumatol Rep       Date:  2003-08       Impact factor: 4.592

2.  Progression of salivary gland dysfunction in patients with Sjogren's syndrome.

Authors:  J Pijpe; W W I Kalk; H Bootsma; F K L Spijkervet; C G M Kallenberg; A Vissink
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

3.  Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both).

Authors:  M Pertovaara; M Korpela; H Uusitalo; J Pukander; A Miettinen; H Helin; A Pasternack
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

4.  Lamivudine is not effective in primary Sjögren's syndrome.

Authors:  B Gescuk; A J Wu; J P Whitcher; T E Daniels; S Lund; K Fye; J C Davis
Journal:  Ann Rheum Dis       Date:  2005-02-11       Impact factor: 19.103

5.  Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry.

Authors:  Caroline H Shiboski; Alan N Baer; Stephen C Shiboski; Mi Lam; Stephen Challacombe; Hector E Lanfranchi; Morten Schiødt; Penelope Shirlaw; Muthiah Srinivasan; Hisanori Umehara; Frederick B Vivino; Esen Akpek; Vatinee Bunya; Cristina F Vollenweider; John S Greenspan; Troy E Daniels; Lindsey A Criswell
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-01-03       Impact factor: 4.794

Review 6.  Parasympathetic nervous system dysfunction in primary Sjögren's syndrome.

Authors:  A Hocevar; M Tomsic; S Praprotnik; M Hojnik; T Kveder; B Rozman
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

7.  Imaging Activated-T-Lymphocytes in the Salivary Glands of Patients with Sjögren's Syndrome by 99mTc-Interleukin-2: Diagnostic and Therapeutic Implications.

Authors:  Giuseppe Campagna; Luz Kelly Anzola; Michela Varani; Chiara Lauri; Guido Gentiloni Silveri; Lorenzo Chiurchioni; Francesca Romana Spinelli; Roberta Priori; Fabrizio Conti; Alberto Signore
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

8.  Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren's syndrome treated with Infliximab: a pilot study.

Authors:  L K Anzola-Fuentes; M Chianelli; F Galli; A W J M Glaudemans; L Martin Martin; V Todino; A Migliore; A Signore
Journal:  EJNMMI Res       Date:  2016-06-04       Impact factor: 3.138

9.  Ultrasonographic Changes of Major Salivary Glands in Primary Sjögren's Syndrome.

Authors:  Kyung-Ann Lee; Sang-Heon Lee; Hae-Rim Kim
Journal:  J Clin Med       Date:  2020-03-16       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.